Tag: 300-400

Formulation and in vitro evaluation of rabeprazole sodium delayed release tablets was written by K., Bhavani;L., Matsyagiri. And the article was included in World Journal of Pharmaceutical Research in 2019.HPLC of Formula: 117976-90-6 The following contents are mentioned in the article:

The main objective of this research work was to formulate and evaluate the delayed release tablets of rabeprazole sodium, an anti ulcer drug like peptic ulcer and duodenal ulcer. Rabeprazole was classI proton pump inhibitor to gain FDA approval. Rabeprazole sodium delayed release tablets were prepared by direct compression technique and dry granulation method. All the Excipients are tested for compatibility with drug, which revealed that there was no phys. and chem. interaction occurred. During film coating Appearance, average weight, hardness, thickness, disintegration and during film coating appearance of film coating, Average weight of film coating tablet, disintegration time and during enteric coating appearance and average weight of enteric coated tablets acid resistance this parameters were performed like wt variation test, hardness, friability, disintegration time. Among all formulations, formulation F12 was found to be best of all the formulations showing drug release matching the innovator product so to that formulation all the quality control tests were done for conformation. Stability study is carried out for 3 mo at 25掳C; 60% RH: and 40掳C; 75% RH, according to ICH guidelines. The effect of these variables on drug release also studied. The in vitro drug release studied was performed in the disintegration apparatus This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6HPLC of Formula: 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.HPLC of Formula: 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Formulation of immediate release tablets of Rabeprazole sodium by using tablet in tablet technology was written by Firoz, Syed. Gouse;Amaragiri Lakshmi, N.;Vasantha Kumari, B.;Swapnamadhuri, P.;Sudha Rani, S.;Karthik, S.. And the article was included in Indo American Journal of Pharmaceutical Sciences in 2021.HPLC of Formula: 117976-90-6 The following contents are mentioned in the article:

Rabeprazole provided effective control of gastric acid in patients with symptoms of gastroesophageal reflux. The present work was carried out to improve the therapeutic efficacy of Rabeprazole by expediting its onset of action. Rabeprazole is unstable in acidic environment which requires the drug in immediate release tablet to be delivered in an alk. environment to enhance the in vivo stability of Rabeprazole. The tablets were prepared by using Tablet-in-Tablet technol., in which the drug was present as inner core and the buffer as the outer layer. A total of four inner core formulations were prepared by direct compression method and evaluated for their phys. parameters. Outer core formulation was prepared using wet granulation method. A total of six tablets in tablet formulations were prepared using A4 as the best inner core formulation depending upon its disintegration time. The prepared tablets were film coated by using Insta moist shield film coating material, to protect the formulation from moisture absorbance. All the six formulations were evaluated and Batch F6 was selected as best formulation and compared with the reference product. The developed tablets were found to be superior to the existing immediate release formulations by providing macro pH environment instead of micro pH ambience with less buffer content. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6HPLC of Formula: 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).HPLC of Formula: 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV) was written by Holzhey, Tanja;Poenisch, Wolfram;Wang, Song-Yau;Holzvogt, Madlen;Holzvogt, Bruno;Andrea, Marc;Zehrfeld, Thomas;Hammerschmidt, Doreen;Hoffmann, Franz Albert;Becker, Cornelia;Schwarzer, Andreas;Schwarz, Maik;Schoenfelder-Fricke, Uta;Edelmann, Thomas;Braunert, Leanthe;Franke, Georg-Nikolaus;Jentzsch, Madlen;Schwind, Sebastian;Bill, Markus;Grimm, Juliane;Remane, Yvonne;Platzbecker, Uwe;Scholz, Markus. And the article was included in Journal of Cancer Research and Clinical Oncology in 2021.Electric Literature of C16H21Cl2N3O2 The following contents are mentioned in the article:

Light chain involvement is observed in almost every patient (pt) with newly diagnosed multiple myeloma (MM). Owing to a relatively short half-life, rapid reduction in the involved free light chain (iFLC) is of potential prognostic value. This retrospective anal. included 92 pts with newly diagnosed MM treated with bendamustine, prednisone, and bortezomib (BPV). After a median number of two (range 1-5) BPV cycles, the majority of pts (n = 86; 93%) responded with either sCR (n = 21), CR (n = 1), nCR (n = 25), VGPR (n = 20), or PR (n = 19). PFS and OS at 48 mo were 39% and 67%, resp. At baseline, 79 out of 92 pts (86%) had iFLC levels above the upper standard level and an abnormal ratio of involved to uninvolved free light chain 鈮?8. In a subgroup anal. of these pts, we evaluated the prognostic importance of an early reduction of the iFLC during the first two BPV cycles. A reduction 鈮?50% of the iFLC on day 8 of the first cycle was observed in 31 of 69 pts. These pts had a significantly better median PFS of 49 mo as compared to 20 mo in 38 pts with a lower iFLC reduction (p = 0.002). In contrast, OS did not differ significantly with a 48 mo survival of 77% vs 69% (p > 0.05). These results indicate that a rapid decrease in the iFLC on day 8 is an early prognostic marker for newly diagnosed MM pts undergoing BPV treatment. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Electric Literature of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Electric Literature of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Ligand based 3D-QSAR model, pharmacophore, molecular docking and ADME to identify potential fibroblast growth factor receptor 1 inhibitors was written by Huang, Lu;Wu, Xulong;Fu, Xiaoli;Wang, Haoxiang;Tang, Biao;Xiao, Yirong;Zhou, Caixia;Zhao, Zhiqiao;Wan, Yujun;Chen, Hui;Tang, Zizhong;Yao, Huipeng;Shan, Zhi;Bu, Tongliang. And the article was included in Journal of Biomolecular Structure and Dynamics in 2022.Application of 117976-90-6 The following contents are mentioned in the article:

The FGF/FGFR system may affect tumor cells and stromal microenvironment through autocrine and paracrine stimulation, thereby significantly promoting oncogene transformation and tumor growth. Abnormal expression of FGFR1 in cells is considered to be the main cause of tumorigenesis and a potential target for the treatment of cancer. In this study, a combination of structure-based drug carriers and mol. docking-based virtual screening was used to screen new potential FGFR1 inhibitors. Forty eight known inhibitors were collected to establish 3 D-QSAR models and pharmacophore models, investigate the relationship between the activity and conformation of compounds, and verify the efficiency of pharmacophore. In Accelrys Discovery Studio 2016, the ZINC database was filtered by Lipinski鈥瞫 Rule of Five and SMART鈥瞫 filtration. Then, Hypo01 was used for virtual screening of ZINC database. Compounds with predicted activity values less than 1 渭M were molecularly docked with FGFR1 protein crystals, the docking results were observed, and the interaction between compounds and targets was studied. The absorption, distribution, metabolism and excretion (ADME) and toxicity of potential inhibitors were studied, and a compound with new structural scaffolds were obtained. It could be further studied to explore their better therapeutic effects. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Application of 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Application of 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study was written by Cull, Gavin;Burger, Jan A.;Opat, Stephen;Gottlieb, David;Verner, Emma;Trotman, Judith;Marlton, Paula;Munoz, Javier;Johnston, Patrick;Simpson, David;Stern, Jennifer C.;Prathikanti, Radha;Wu, Kenneth;Novotny, William;Huang, Jane;Tam, Constantine S.. And the article was included in British Journal of Haematology in 2022.Product Details of 16506-27-7 The following contents are mentioned in the article:

Summary : The phase I/II AU-003 study in patients with treatment-naive (TN) or relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma demonstrated that zanubrutinib therapy results in clin. meaningful and durable responses with acceptable safety and tolerability. We report updated safety and efficacy data for 123 patients with a median follow-up of 47路2 mo. Patients received zanubrutinib 160 mg twice daily (81 patients), 320 mg once daily (40), or 160 mg once daily (two). Discontinuations due to adverse events or disease progression were uncommon. The overall response rate (ORR) was 95路9% (TN, 100%; R/R, 95%) with 18路7% achieving complete response (CR). Ongoing response at 3 years was reported in 85路7%. The ORR in patients with del(17p)/tumor protein p53 mutation was 87路5% (CR 16路7%). The 2- and 3-yr progression-free survival estimates were 90% (TN, 90%; R/R, 91%) and 83% (TN, 81%; R/R, 83%) resp. The most reported Grade 鈮? adverse events were neutropenia (15路4%), pneumonia (9路8%), hypertension (8路9%) and anemia (6路5%). The annual incidence of atrial fibrillation, major hemorrhage, Grade 鈮? neutropenia and Grade 鈮? infection decreased over time. With a median follow-up of 鈭? years, responses remain clin. meaningful and durable and long-term tolerability to zanubrutinib therapy continues. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Product Details of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Product Details of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long-term prospective follow-up study was written by Kodama, Masaaki;Okimoto, Tadayoshi;Mizukami, Kazuhiro;Hirashita, Yuka;Wada, Yasuhiro;Fukuda, Masahide;Matsunari, Osamu;Okamoto, Kazuhisa;Ogawa, Ryo;Fukuda, Kensuke;Kudo, Yoko;Kawahara, Yoshinari;Murakami, Kazunari. And the article was included in Journal of Gastroenterology and Hepatology in 2021.Safety of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

Improvement of atrophic gastritis and intestinal metaplasia (IM) is considered to reduce the gastric cancer risk, but whether it can be achieved by H. pylori eradication (HPE) remains controversial. To evaluate the effect of HPE, we observed the gastric mucosa for up to17 years after HPE and sex differences in gastric mucosa. In total, 172 patients (94 males, 78 females) with HPE were enrolled. Annual histol. evaluations were performed for up to 17 years. The grades of mononuclear cells, neutrophils, atrophy, IM in the antrum and corpus were evaluated using the updated Sydney system. Pre-HPE period, atrophy had improved significantly 1 yr after HPE in the antrum (1.50 卤 0.75 vs. 1.21 卤 1.25, P < 0.01) and corpus (0.59 卤 0.75 vs. 0.18 卤 0.52, P < 0.05). IM showed no significant change during 17 years after HPE at either biopsy site. Atrophy scores did not differ significantly between males and females. IM scores were significantly higher in males than in females before eradication (antrum, 0.67 卤 0.94 vs. 0.44 卤 0.77, P = 0.003, corpus, 0.20 卤 0.62 vs. 0.047 卤 0.21, P = 0.0027) and at most observation timepoints. During 17 years after HPE, atrophy, but not IM, improved significantly at the greater curvatures of the antrum and corpus. IM was significantly more severe in males than in females. Careful follow-up after HPE based on sex differences in gastric mucosal characteristics is important. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Safety of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Safety of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer was written by Matsuoka, Hiroya;Ando, Koji;Swayze, Emma J.;Unan, Elizabeth C.;Mathew, Joseph;Hu, Quingjiang;Tsuda, Yasuo;Nakashima, Yuichiro;Saeki, Hiroshi;Oki, Eiji;Bharti, Ajit K.;Mori, Masaki. And the article was included in PLoS One in 2020.Reference of 117976-90-6 The following contents are mentioned in the article:

Irinotecan specifically targets topoisomerase I (topoI), and is used to treat various solid tumors, but only 13-32% of patients respond to the therapy. Now, it is understood that the rapid rate of topoI degradation in response to irinotecan causes irinotecan resistance. We have published that the deregulated DNA-PKcs kinase cascade ensures rapid degradation of topoI and is at the core of the drug resistance mechanism of topoI inhibitors, including irinotecan. We also identified CTD small phosphatase 1 (CTDSP1) (a nuclear phosphatase) as a primary upstream regulator of DNA-PKcs in response to topoI inhibitors. Previous reports showed that rabeprazole, a proton pump inhibitor (PPI) inhibits CTDSP1 activity. The purpose of this study was to confirm the effects of rabeprazole on CTDSP1 activity and its impact on irinotecan-based therapy in colon cancer. Using differentially expressing CTDSP1 cells, we demonstrated that CTDSP1 contributes to the irinotecan sensitivity by preventing topoI degradation Retrospective anal. of patients receiving irinotecan with or without rabeprazole has shown the effects of CTDSP1 on irinotecan response. These results indicate that CTDSP1 promotes sensitivity to irinotecan and rabeprazole prevents this effect, resulting in drug resistance. To ensure the best chance at effective treatment, rabeprazole may not be a suitable PPI for cancer patients treated with irinotecan. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Reference of 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Reference of 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Rp-hplc method development and validation for simultaneous estimation of clidinium bromide, chlordiazepoxide, dicyclomine hcl and rabeprazole sodium in pharmaceutical dosage form was written by Khan, Ummekulsum;Luhar, Shailesh V.;Narkhede, Sachin B.. And the article was included in European Journal of Biomedical and Pharmaceutical Sciences in 2018.Synthetic Route of C18H20N3NaO3S The following contents are mentioned in the article:

A simple, rapid, economical, precise and accurate RP-HPLC method for simultaneous estimation of Clidinium Bromide, Chlordiazepoxide, Dicyclomine HCl and Rabeprazole Sodium has been developed. Method was studied by using Shimadzu 2010CHT, Chromatog. separation was achieved using ODS C18 RP column (250 mm 脳 4.6 mm i.d., 5渭m) kept at ambient temperature, using a mobile phase consisting a mixture of Phosphate buffer (pH 4.5): Acetonitrile (80:20 volume/volume) and pH adjusted with 0.5% orthophosphoric acid at a flow rate of 1.0 mL/min. The detection was made at 215 nm. Retention time was 3.12 min, 4.28 min and 6.97 min and 13.29 for Clidinium Bromide, Chlordiazepoxide, Dicyclomine HCl and Rabeprazole Sodium resp. Linear correlation was obtained between peak area and concentration in the range of 5-15 渭g/mL for Clidinium Bromide, 10-30 渭g/mL for Chlordiazepoxide, 20-60 渭g/mL for Dicyclomine HCl and Rabeprazole Sodium. The percentage recoveries of four drugs Clidinium Bromide, Chlordiazepoxide, Dicyclomine HCl and Rabeprazole Sodium were found to be 100.48-101.46 %, 98.87-101.75%,98.20-98.80% and 100.94-101.71 % resp. The % RSD value was less than 2, for intraday and interday precision. It can be successfully used for routine anal. of Clidinium Bromide, Chlordiazepoxide, Dicyclomine HCl and Rabeprazole Sodium in combined solid dosage form without any interference from common excipients and impurity. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Synthetic Route of C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Synthetic Route of C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Impact of rituximab on COVID-19 outcomes was written by Levavi, Hannah;Lancman, Guido;Gabrilove, Janice. And the article was included in Annals of Hematology in 2021.Reference of 16506-27-7 The following contents are mentioned in the article:

Rituximab is associated with prolonged B-cell depletion and secondary hypogammaglobulinemia and is associated with a dampened humoral response and increased infectious complications. To describe the potential impact of prior rituximab therapy on clin. outcomes from SARS-CoV-2 infection and development of COVID-19 antibodies, we conducted a retrospective study of adults across the Mount Sinai Health System diagnosed with COVID-19 who received rituximab for any indication from Feb. 2019 to Oct. 2020. Patients’ baseline characteristics, markers of disease severity, clin. outcomes, and antibody development were examined Of the 49 patients included in the anal., 63.2% required hospitalization for COVID-19, 24.5% required an ICU admission, and 32.7% died. Proximity of last rituximab infusion and COVID-19 diagnosis did not affect rates of hospitalization, admission to intensive care units or death. Over half (51.7%) of those whose antibodies were checked developed neutralizing anti-spike protein antibodies. The median time between rituximab administration and COVID-19 diagnosis was not significantly different between those who developed antibodies and those who did not (p = .323). Of the 14 patients with documented neg. COVID-19 antibody titers, 11 of them survived SARS-CoV-2 infection, indicating that development of neutralizing antibodies may not be necessary for recovery from COVID-19. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Reference of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Reference of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Proton Pump Inhibitors and Bone Health: An Update Narrative Review was written by Lespessailles, Eric;Toumi, Hechmi. And the article was included in International Journal of Molecular Sciences in 2022.Recommanded Product: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

Proton pump inhibitors (PPIs) are an antacid drug often used in acid-related disorders. They decrease acid secretion in the stomach by blocking an enzyme called H+/K+ ATPase which controls acid production Introduced to the market in 1989, their use has increased rapidly worldwide and they are now among the top 10 most prescribed drugs in the United States. As of 2015, the FDA has already approved six drugs of this class (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole and rabeprazole). Recently, the risks and benefits of long-term PPI use were questioned and many studies indicated that their use should be carefully considered, especially in young patients, whose treatment with these drugs could last many years. Even greater concerns have been raised about a potential pos. association between PPIs and osteoporotic fracture risk including the hip, spine and wrist. Although based on observational studies, there is substantial evidence associating the long-term use of PPIs and fracture. This relationship is only partially admitted due to the lack of consistent effects of PPIs on bone mineral d. loss. Therefore, this narrative review aimed to discuss the recent findings pertaining to the risk of osteoporotic fracture associated with PPIs, in particular prolonged use, and to call for further research to elucidate the mechanisms associated with this bone fragility. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Recommanded Product: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3鈥揅6) is higher than in water and generally decreases with a Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Recommanded Product: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem